Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

杜皮鲁玛 医学 特应性皮炎 皮肤病科
作者
Margitta Worm,Eric L. Simpson,Diamant Thaçi,Robert Bissonnette,J.‐P. Lacour,Stefan Beissert,Makoto Kawashima,Carlos Ferrándiz,Catherine Smith,Lisa A. Beck,Kuo‐Chen Chan,Zhen Chen,Bolanle Akinlade,Thomas Hultsch,Heribert Staudinger,Abhijit Gadkari,Laurent Eckert,John D. Davis,Manoj Rajadhyaksha,Neil M.H. Graham
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:156 (2): 131-131 被引量:155
标识
DOI:10.1001/jamadermatol.2019.3617
摘要

The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD).To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment.The Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (LIBERTY AD SOLO-CONTINUE) was a randomized, double-blind, phase 3 clinical trial conducted from March 25, 2015, to October 18, 2016, at 185 sites in North America, Europe, Asia, and Japan. Patients with moderate to severe AD who received dupilumab treatment and achieved an Investigator's Global Assessment score of 0 or 1 or 75% improvement in Eczema Area and Severity Index scores (EASI-75) at week 16 in 2 previous dupilumab monotherapy trials (LIBERTY AD SOLO 1 and 2) were rerandomized in SOLO-CONTINUE. After completing SOLO-CONTINUE, patients were followed up for up to 12 weeks or enrolled in an open-label extension. Data were analyzed from December 5 to 12, 2016.High-responding patients treated with dupilumab in SOLO were rerandomized 2:1:1:1 to continue their original regimen of dupilumab, 300 mg, weekly or every 2 weeks or to receive dupilumab, 300 mg, every 4 or 8 weeks or placebo for 36 weeks.Percentage change in EASI score from baseline during the SOLO-CONTINUE trial, percentage of patients with EASI-75 at week 36, and safety.Among the 422 patients (mean [SD] age, 38.2 [14.5] years; 227 [53.8%] male), continuing dupilumab treatment once weekly or every 2 weeks maintained optimal efficacy, with negligible change in percent EASI improvement from SOLO 1 and 2 baseline during the SOLO-CONTINUE trial (-0.06%; P < .001 vs placebo); percent change with the other regimens dose-dependently worsened (dupilumab every 4 weeks, -3.84%; dupilumab every 8 weeks, -6.84%; placebo, -21.67%). More patients taking dupilumab weekly or every 2 weeks (116 of 162 [71.6%]; P < .001 vs placebo) maintained EASI-75 response than those taking dupilumab every 4 weeks (49 of 84 [58.3%]) or every 8 weeks (45 of 82 [54.9%]) or those taking placebo (24 of 79 [30.4%]). Overall adverse event incidences were 70.7% in the weekly or every 2 weeks group, 73.6% in the every 4 weeks group, 75.0% in the every 8 weeks group, and 81.7% in the placebo group. Treatment groups had similar conjunctivitis rates. Treatment-emergent antidrug antibody incidence was lower with more frequent dupilumab dose regimens (11.3% in the placebo group and 11.7%, 6.0%, 4.3%, and 1.2% in the dupilumab every 8 weeks, every 4 weeks, every 2 weeks, and weekly groups, respectively).In this trial, continued response over time was most consistently maintained with dupilumab administered weekly or every 2 weeks. Longer dosage intervals and placebo resulted in a diminution of response for both continuous and categorical end points. No new safety signals were observed. The approved regimen of 300 mg of dupilumab every 2 weeks is recommended for long-term treatment.ClinicalTrials.gov identifier: NCT02395133.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
逝水无痕完成签到,获得积分10
刚刚
充电宝应助tanliulong采纳,获得10
刚刚
忆仙姿完成签到,获得积分10
刚刚
共享精神应助qweasdzxcqwe采纳,获得10
3秒前
3秒前
苏楠完成签到,获得积分10
4秒前
张成关注了科研通微信公众号
4秒前
天天快乐应助哎呀呀采纳,获得10
4秒前
Mira完成签到,获得积分10
6秒前
UniTTEC9560完成签到,获得积分10
6秒前
8秒前
cc完成签到,获得积分10
8秒前
无生发布了新的文献求助10
8秒前
无花果应助欣慰的乌冬面采纳,获得10
9秒前
9秒前
10秒前
Ava应助dhjic采纳,获得10
11秒前
11秒前
11秒前
12秒前
清风完成签到 ,获得积分10
13秒前
无辜忆寒完成签到,获得积分10
13秒前
14秒前
易子发布了新的文献求助10
15秒前
15秒前
如意的听云完成签到,获得积分10
15秒前
妖精完成签到 ,获得积分10
16秒前
刘无敌发布了新的文献求助10
16秒前
17秒前
19秒前
19秒前
汉堡包应助吴祥坤采纳,获得10
20秒前
20秒前
23秒前
luo发布了新的文献求助10
23秒前
王番完成签到,获得积分10
24秒前
24秒前
24秒前
普贤行发布了新的文献求助10
24秒前
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975661
求助须知:如何正确求助?哪些是违规求助? 3520000
关于积分的说明 11200535
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798247
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390